Coartem receives FDA approval becoming first artemisinin-based combination treatment (ACT) for malaria in the US
"Around the world, Coartem has eliminated suffering for millions and saved lives for hundreds of thousands of malaria patients," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "With a growing number of malaria cases in the US due to rising travel, it is important to make ACT treatment such as Coartem, the most effective therapy for malaria, available to American patients as well."
In the US, Coartem will be made available through pharmacies and hospitals.
Coartem is indicated for the treatment of acute uncomplicated infections due to plasmodium falciparum, the most dangerous form of malaria.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.